A nationwide Class II recall covers 15 cough-drop products sold under five store and health-product brands, according to records published by the U.S. Food and Drug Administration. Xiamen Kang Zhongyuan Biotechnology Co., Ltd., the China-based manufacturer, agreed to remove certain mentholated cough-drop lots from the U.S. market after discussions with the agency.

The affected products carry the Exchange Select, Caring Mill, Discount Drug Mart, MGC Health and QC Quality Choice names. The action is not a blanket recall of every cough drop sold by those brands. A package is included only if its identifying details match a listed product and lot.

The recall began on March 20, 2026, and was later classified as Class II. That classification is used when exposure may cause temporary or medically reversible health effects, or when the likelihood of serious harm is remote. It describes the agency's risk assessment; it does not establish that every recalled package caused an injury.

Products and Lots Included in the Recall

Consumers should compare the brand, flavor, package size, lot number, expiration date and UPC on the package. The recall list reported from FDA enforcement records includes:

  • Exchange Select Honey Lemon, 30-count: lot 20241030, expiration 10/30/2026, UPC 614299398870.
  • Exchange Select Menthol, 30-count: lot 20241030, expiration 10/30/2026, UPC 614299398887.
  • Caring Mill Cherry, 90-count: lot 20241030, expiration 10/30/2026, UPC 810025928407.
  • Discount Drug Mart Honey Lemon, 30-count: lot 20241030, expiration 10/30/2026, UPC 093351037092.
  • Discount Drug Mart Menthol, 30-count: lot 20241030, expiration 10/30/2026, UPC 093351037085.
  • MGC Health Sugar Free Honey Lemon, 25-count: lot 20240524 expiring 05/24/2026, lot 20240720 expiring 07/20/2026 and lot 20240730 expiring 07/30/2026; UPC 383173000085.
  • MGC Health Honey Lemon, 30-count: lot 20240524, expiration 05/24/2026, UPC 383173000047.
  • MGC Health Honey Lemon, 80-count: lot 20240730, expiration 07/30/2026, UPC 383173000030.
  • QC Quality Choice Sugar Free Black Cherry, 25-count: lot 20240720, expiration 07/20/2026, UPC 635515993372.
  • QC Quality Choice Cherry, 30-count: lot 20240524 expiring 05/24/2026 and lot 20240720 expiring 07/20/2026; UPC 635515993372.
  • QC Quality Choice Sugar Free Honey Lemon, 25-count: lot 20240720 expiring 07/20/2026 and lot 20241030 expiring 10/30/2026; UPC 635515993372.
  • QC Quality Choice Creamy Strawberry Throat Soothing Drops, 30-count: lot 20240720, expiration 07/20/2026, UPC 635515999398.
  • QC Quality Choice Honey Lemon, 30-count: lot 20240720, expiration 07/20/2026, UPC 63551598673.
  • QC Quality Choice Menthol, 30-count: lot 20240720 expiring 07/20/2026 and lot 20240524 expiring 05/24/2026; UPC 635515986718.
  • QC Quality Choice Vanilla Honey, 30-count: lot 20240720, expiration 07/20/2026, UPC 635515999411.

Several entries share a brand or UPC while covering different flavors, sizes or lots. Checking only the brand name is therefore insufficient. The lot and package details are what separate recalled stock from products outside the action.

What FDA Inspectors Documented

The FDA inspected Xiamen Kang Zhongyuan Biotechnology's drug-manufacturing facility in Xiamen, China, from August 12 through August 15, 2025. In a warning letter dated March 23, 2026, the agency said products made there were prepared, packed or held under insanitary conditions and were therefore considered adulterated under federal law.

Inspectors recorded grime and discolored lubricant on manufacturing equipment, standing water in a production area and inside equipment marked as clean, a dirty transfer tube, unidentified droplets above manufacturing equipment, flies, a live cockroach in a packaging area and apparent mold on air-conditioning vents in a storage area.

The warning letter also describes data-integrity concerns. According to the FDA, the company's chief quality officer admitted providing false documents related to finished-product testing. Investigators also said manufacturing records supplied during the inspection contained information that had not appeared when the same logbook was first requested. The agency found the company's response inadequate because it did not include a sufficiently broad review of possible product-quality and recordkeeping risks.

How the Recall Developed

The FDA held a teleconference with the manufacturer on March 4 and recommended that it consider removing batches of mentholated cough drops then in U.S. distribution. The company agreed to initiate a recall of certain lots. On March 20, the agency also placed drugs offered for U.S. import by the firm on Import Alert 66-40, which permits detention without physical examination when applicable.

Those dates matter because the recall and the import action are related but distinct. The recall addresses identified lots already in distribution. The import alert concerns future shipments offered for entry. Neither action supports extending the warning to unrelated cough-drop brands or to Chinese-made medicines generally.

The Safety Record Must Stay Product-Specific

The strongest case for scrutiny comes from the FDA's own inspection record: visible sanitation failures, possible lubricant contamination and acknowledged problems with testing documents. Those findings justify a precise account of what regulators saw and which products were pulled. They do not justify replacing product identification with rhetoric about nationality or the entire over-the-counter medicine market.

A recall notice succeeds only when a reader can act on it. Omitting brands and lots while making broad claims about retail distribution or manufacturing reverses the proper order of priorities. For a health-related recall, the useful facts are the package identifiers, the agency's stated reason, the risk classification and the limits of what is known. Anything broader requires separate evidence.